15 - 17 February, 2012, London, UK
Register by January 20 2012* and receive up to £200off!
Download the Info Pack
Access our Download Centre
Become a Pharma IQ Member and receive our weekly newsletter!
Connect to a global Pharma IQ social network
Learn more about sponsor & exhibit opportunities
Mark Your Calendar
Tell a Colleague
Laszlo Urban, Preclinical Safety ProfilingNIBR, Cambridge, Ma. presents: How To Mitigate Cardiac Toxicity During Lead Selection And Lead Optimization?
Paul Hastwell, Safety Assessment, GSK
Frank W Bonner, Stem Cell for Safer Medicines (SC4SM) presents: Exploring the Potential of Stem Cell Assays in Predictive Toxicology Testing
James A. Dykens, Investigative Toxicity Drug Safety Research & Development Sandwich, UK
Glyn Stacey, NIBSC-HPA presents: UK Stem Cell Bank: Supporting the Development of Stem Cell Models for Safety Testing.
M.B. Friedman, PhD, DABT Director of Toxicology
David R Jones, Expert Scientific Assessor (Pharmacotoxicologist), Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), UK presents: Predictive Toxicology A Regulatory View
Vasily Dobrovolsky, Division of Genetic and Reproductive Toxicology, National Center for Toxicological Reasearch USFDA(DGRT/NCTR/FDA)
25+ world-leading international experts…
Manfred Kansy till recently was heading the Structure/Property Effect Relationships group at F. Hoffmann-La Roche Ltd. Non-Clinical Safety, Basel, Switzerland. He is currently taking over another important task in the NCS organization. The S/PER team concentrated on compound profiling, data interpretation and in silico tool development in the lead selection and optimization phases of drug discovery. Major focus of the multidisciplinary team was directed to more predictive safety in silico prediction and ranking tools, allowing an early identification of potential drug safety liabilities via computational methods.
Associate Director, Non-Clinical Safety
Jens-Uwe Peters is a medicinal chemist in the Discovery Chemistry department of F. Hoffmann-La Roche Ltd in Basel, Switzerland. Over the last 10 years, he has been involved in numerous drug discovery projects, including several projects in which pharmacological promiscuity was a key issue. He has also contributed to an Early Safety Profiling initiative, in which safety panel profiling was an important aspect.
[ Register Now ]
Questions? Contact us on 0800 652 2363 or +44 (0) 20 7368 9300 or email firstname.lastname@example.org now!